BioSpace News Archive

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced financial results for the fourth quarter and full-year ended December 31, 2023, and provided a business update.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024.

Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today reported financial results for its fiscal fourth quarter and full year ended December 31, 2023 and recent business highlights.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for the treatment of multiple myeloma to P-BCMA-ALLO1, a novel BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate.

Trevi Therapeutics, Inc. (Nasdaq: TRVI) today announced that senior management will host a conference call and live audio webcast on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company’s financial results for the quarter and year ended December 31, 2023.

Outset Medical, Inc., a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, announced the appointment of medical technology veteran Brent D. Lang to its board of directors.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.

Spruce Biosciences, Inc. announced topline results from its CAHmelia-203 study of tildacerfont in adult classic congenital adrenal hyperplasia and its CAHptain-205 study of tildacerfont in pediatric classic CAH.

Orexo AB, has successfully issued new senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years.

MedMira Inc. announces the receipt of a Canadian patent patent for its new innovative and quantitative test system.